- Molecular NameMethyldopa
- SynonymAlpha medopa; Alphamethyldopa; AMD; L-Methyl Dopa; Methyldopa anhydrous; Methyldopate; Methyldopate HCL; Mk; b51
- Weight211.217
- Drugbank_IDDB00968
- ACS_NO555-30-6
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-2.26
- pka2.2 (-COOH), 9.2 (-OH), 10.6(-NH2), 12.0 (-OH), (25°)
- LogD (pH=7, predicted)-2.26
- Solubility (experiment)10 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.65
- LogSw (predicted, AB/LogsW2.0)4.26
- Sw (mg/ml) (predicted, ACD/Labs)4.65
- No.of HBond Donors5
- No.of HBond Acceptors5
- No.of Rotatable Bonds3
- TPSA103.78
- StatusFDA approved
- AdministrationOral, IV
- PharmacologyA psychoactive drug used as a sympatholytic or antihypertensive. Its use is now deprecated following introduction of alternative safer classes of agents. However, it continues to have a role in otherwise difficult to treat hypertension and gestational hypertension (also known as pregnancy-induced hypertension (PIH)).
- Absorption_value50.0
- Absorption (description)Absorption from the gastrointestinal tract is variable but averages approximately 50%.
- Caco_2N/A
- Bioavailability35.0
- Protein binding20.0
- Volume of distribution (VD)0.6 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt is metabolized in the liver
- Half life2 h; a longer terminal elimination half-life has also been reported.
- ExcretionRenal for metabolites
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySymptoms of overdose include bloating, constipation, diarrhea, dizziness, extreme drowsiness, gas, light-headedness, nausea, severely low blood pressure, slow heartbeat, vomiting, and weakness.
- LD50 (rat)LD50>1.5 g/kg
- LD50 (mouse)LD50>1.5 g/kg